GeneCentric Therapeutics ExpressCT Liquid Biopsy Platform

GeneCentric Therapeutics has launched the ExpressCT (Expression Signatures Through Circulating Tumor Signals) liquid biopsy platform, a development tool that adapts RNA-based gene expression signatures to cell-free DNA liquid biopsy assays in order to provide insights beyond DNA mutations. The firm has so far developed liquid biopsy cfDNA signature tests for pancreatic, lung, breast, and colon cancer and is partnering with other firms with suitable liquid biopsy assays to use the ExpressCT technology.